Cargando…
Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant treatment were controversial and conflicting. We p...
Autores principales: | Rizzo, Alessandro, Cusmai, Antonio, Massafra, Raffaella, Bove, Samantha, Comes, Maria Colomba, Fanizzi, Annarita, Rinaldi, Lucia, Acquafredda, Silvana, Gadaleta-Caldarola, Gennaro, Oreste, Donato, Zito, Alfredo, Giotta, Francesco, Lorusso, Vito, Palmiotti, Gennaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221459/ https://www.ncbi.nlm.nih.gov/pubmed/35740985 http://dx.doi.org/10.3390/cells11121857 |
Ejemplares similares
-
Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers
por: Rizzo, Alessandro, et al.
Publicado: (2022) -
Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
por: Rizzo, Alessandro, et al.
Publicado: (2022) -
An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients’ Age: A Retrospective Cohort Study
por: Massafra, Raffaella, et al.
Publicado: (2022) -
Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI
por: La Forgia, Daniele, et al.
Publicado: (2021) -
Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
por: Gadaleta-Caldarola, Gennaro, et al.
Publicado: (2022)